Half-life extension via ABD-fusion leads to higher tumor uptake of an affibody-drug conjugate compared to PAS- and XTENylation.-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Half-life extension via ABD-fusion leads to higher tumor uptake of an affibody-drug conjugate compared to PAS- and XTENylation.

Published:2024-06 Issue: Volume:370 Page:468-478
ISSN:0168-3659
Container-title:Journal of Controlled Release
language:en
Short-container-title:Journal of Controlled Release

Author:

Zhang Jie,Bodenko Vitalina,Larkina Maria,Bezverkhniaia Ekaterina,Xu Tianqi,Liao Yunqi,Abouzayed Ayman,Plotnikov Evgenii,Tretyakova Maria,Yuldasheva Feruza,Belousov Mikhail V.,Orlova Anna,Tolmachev Vladimir,Gräslund Torbjörn,Vorobyeva Anzhelika

Publisher

Elsevier BV

Reference31 articles.

1. Current strategies in extending half-lives of therapeutic proteins;Zaman;J. Control. Release,2019

2. A comprehensive review of the neonatal fc receptor and its application in drug delivery;Martins;Pharmacol. Ther.,2016

3. PASylation: a biological alternative to PEGylation for extending the plasma half-life of pharmaceutically active proteins;Schlapschy;Protein Eng. Des. Sel.,2013

4. A recombinant polypeptide extends the in vivo half-life of peptides and proteins in a tunable manner;Schellenberger;Nat. Biotechnol.,2009

5. Influence of size and charge of unstructured polypeptides on pharmacokinetics and biodistribution of targeted fusion proteins;Brandl;J. Control. Release,2019

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP